<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00942318</url>
  </required_header>
  <id_info>
    <org_study_id>0816202</org_study_id>
    <secondary_id>AOL 2008</secondary_id>
    <nct_id>NCT00942318</nct_id>
  </id_info>
  <brief_title>Efficacy of Continuous Subcutaneous Insulin Infusion Versus Basal-bolus Multiple Daily Injections Regimen in Type 2 Diabetes</brief_title>
  <official_title>Efficacy of Continuous Subcutaneous Insulin Infusion Versus Basal-bolus Multiple Daily Injections Regimen in Type 2 Diabetes: a One Year, Randomised, Parallel Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A lot of insulin-treated type 2 diabetic patients do not reach adequate glycemic control
      despite intensive basal-bolus insulin regimen. In such cases, continuous subcutaneous insulin
      infusion (CSII), using an external pump, could be a solution to improve diabetes control.

      The aim of this study is to compare, over a one-year period, the efficacy of CSII (with
      aspart insulin) and basal-bolus multiple daily injections (MDI) treatment (with detemir x 2/d
      and aspart before meals) in type 2 diabetic patients, already treated by basal-bolus regimen
      for at least 6 months, who didn't reach adequate target for glycemic at baseline (HbA1c&gt;7
      -10%).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Visit 1: patient information and eligibility criteria assessment Visit 2: Inform consent
      signature and randomisation (group CSII or MDI). Patients randomised in the CSII group are
      instructed to use pump between V2 and V3.

      Visit 3: 5-day's hospitalisation. Start of CSII or MDI treatments. Stop of all oral diabetic
      medications except for metformin, which is followed up until the end of the study. Teaching
      program on diabetes management (diet, physical activity and self-adjustment of insulin
      doses). HbA1c, clinical and biological parameters. Questionnaires.

      Follow-up visits 4-7 (1, 3, 6, 9 months): HbA1c. Treatment adjustment. Adverse events
      collection.

      Final visit (12 months): HbA1c, clinical and biological parameters. Questionnaires. Adverse
      events collection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight, waist perimeter, BP, triglycerides, total cholesterol, HDL and LDL cholesterol ; QOL, physical activity, treatment satisfaction and eating habits questionnaire.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>self monitoring blood glucose measurements (frequency, mean and standard deviation, number of hypoglycaemic and hyperglycaemic events)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>PPE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PPE : CSII +/- Metformin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>injections</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>INJ: basal/bolus MDI +/- Metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Detemir insulin, Aspart insulin, Metformin</intervention_name>
    <description>Insulin doses adapted by patients according to self monitoring blood glucose results.</description>
    <arm_group_label>PPE</arm_group_label>
    <arm_group_label>injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes mellitus

          -  Age &gt; 18 years

          -  Patients treated for at least 6 months by Multiple daily insulin injections
             associating long acting insulin (at least 1 long acting insulin analog injection
             -Glargine or Detemir- or at least 2 NPH insulin injections) plus mealtimes rapid
             acting insulin injections (Human or analogs) +/- oral hypoglycemic agents.

          -  7,5% ≤ HbA1c ≤ 10%

          -  Patients able to perform self-monitoring blood glucose (SMBG) measurement and insulin
             injections.

          -  SMBG &gt; 3/day

        Exclusion Criteria:

          -  Diabetic retinopathy contraindicating glycemic control intensification

          -  Situation or pathology not allowing therapeutic education program (blindness,
             deafness, low language fluency…)

          -  Situation or pathology not allowing insulin therapy self-management and / or portable
             insulin pump use (rheumatologic pathology, low visual acuity, …)

          -  Recent (&lt;3 month) serious pathology

          -  Planned treatment or therapy able to induce long-term glycemic control worsening

          -  Long lasting (&gt; 2 month) planned treatment with glucocorticoids, octreotide,
             lanreotide or danazol

          -  Pregnancy wish or ongoing pregnancy

          -  Known Haemoglobinopathy.

          -  Creatinin clearance &lt;30ml/min (MDRD formula).

          -  Organ transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Melki, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2009</study_first_submitted>
  <study_first_submitted_qc>July 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2009</study_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Continuous subcutaneous insulin infusion</keyword>
  <keyword>Insulin external pump</keyword>
  <keyword>Multiple daily injections</keyword>
  <keyword>Basal-bolus regimen</keyword>
  <keyword>Education</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

